{"id":390125,"date":"2020-12-23T00:00:00","date_gmt":"2020-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0008-2020-biopharma-prostate-cancer-china-in-depth-2020\/"},"modified":"2026-03-31T10:44:06","modified_gmt":"2026-03-31T10:44:06","slug":"concon0008-2020-biopharma-prostate-cancer-china-in-depth-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0008-2020-biopharma-prostate-cancer-china-in-depth-2020\/","title":{"rendered":"Prostate Cancer | China In-Depth | 2020"},"content":{"rendered":"<p>Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence of prostate cancer\u00a0throughout China. The drug-treatment rate has increased over the last few years owing to strong uptake of novel premium-priced therapies and these drugs&#8217; inclusion in the NRDL in the 2017 update, especially abiraterone (Janssen\u2019s Zytga). Most recent drug approvals in China (e.g., enzalutamide [Astella\u2019s Xtandi], apalutamide [Janssen\u2019s Erleada], degarelix [Ferring Pharma\u2019s Firmagon] underscore manufacturers&#8217; focus on the prostate cancer therapy market in China. Multilabel expansions of marketed drugs to new patient populations are expected.<\/p>\n<ul>\n<li>How large is China\u2019s drug-treatable prostate cancer population, and how will drug-treatment rates change during the forecast period?<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s prostate cancer market and why? What are interviewed experts\u2019 insights into current treatment options? Which clinical needs remain unfulfilled?<\/li>\n<li>What are the market access considerations for key therapies in the prostate cancer pipeline in China? What sales\/uptake could these agents secure in prostate cancer? What are interviewed experts\u2019 opinions of these therapies?<\/li>\n<li>What are the key drivers and constraints in the Chinese prostate cancer therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p><em>China In-Depth<\/em> offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&#038;R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n<p><strong>RELEASE DATE<\/strong><\/p>\n<p>December 2020<\/p>\n<p><strong>GEOGRAPHY<\/strong><\/p>\n<p>China<\/p>\n<p><strong>PRIMARY RESEARCH<\/strong><\/p>\n<p>Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with medical oncologists and urologists. Supported by survey data collected for this and other DRG research.<\/p>\n<p><strong>EPIDEMIOLOGY<\/strong><\/p>\n<p>Diagnosed incidence of prostate cancer in urban versus rural China; clinically relevant and market-relevant, drug-treatable populations.<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales and patient shares of key prostate cancer agents through 2029, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p><strong>EMERGING THERAPIES<\/strong><\/p>\n<p>Phase III\/PR: 10+ drugs; Phase II: 1 drug<\/p>\n","protected":false},"template":"","class_list":["post-390125","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390125\/revisions"}],"predecessor-version":[{"id":576457,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390125\/revisions\/576457"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}